$208.23
+4.68
(+2.3%)▲
Live
Revenue is up for the last 12 quarters, 204.99M → 434.07M (in $), with an average increase of 6.5% per quarter
Netprofit is up for the last 4 quarters, 49.36M → 72.89M (in $), with an average increase of 11.6% per quarter
1.95%
Downside
Day's Volatility :2.11%
Upside
0.16%
37.19%
Downside
52 Weeks Volatility :45.84%
Upside
13.77%
Period | Medpace Holdings, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 4.99% | 0.3% | -6.7% |
6 Months | -3.02% | -8.3% | -6.2% |
1 Year | 42.1% | -4.8% | -6.3% |
3 Years | 127.13% | 23.8% | 26.9% |
Market Capitalization | 6.2B |
Book Value | $11.37 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | 7.92 |
PE Ratio | 25.7 |
PEG Ratio | 1.97 |
Wall Street Target Price | 224.75 |
Profit Margin | 16.44% |
Operating Margin TTM | 19.24% |
Return On Assets TTM | 13.72% |
Return On Equity TTM | 53.97% |
Revenue TTM | 1.6B |
Revenue Per Share TTM | 49.76 |
Quarterly Revenue Growth YOY | 31.2% |
Gross Profit TTM | 925.1M |
EBITDA | 323.9M |
Diluted Eps TTM | 7.92 |
Quarterly Earnings Growth YOY | 0.34 |
EPS Estimate Current Year | 8.2 |
EPS Estimate Next Year | 9.35 |
EPS Estimate Current Quarter | 1.8 |
EPS Estimate Next Quarter | 1.83 |
What analysts predicted
Upside of 7.93%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 436.2M | ↑ 3.46% |
Net Income | 39.1M | ↑ 191.41% |
Net Profit Margin | 8.97% | ↑ 5.79% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 704.6M | ↑ 61.55% |
Net Income | 73.2M | ↑ 87.07% |
Net Profit Margin | 10.39% | ↑ 1.42% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 861.0M | ↑ 22.19% |
Net Income | 100.4M | ↑ 37.25% |
Net Profit Margin | 11.67% | ↑ 1.28% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 925.9M | ↑ 7.54% |
Net Income | 145.4M | ↑ 44.74% |
Net Profit Margin | 15.7% | ↑ 4.03% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 23.38% |
Net Income | 181.8M | ↑ 25.08% |
Net Profit Margin | 15.92% | ↑ 0.22% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 27.8% |
Net Income | 245.4M | ↑ 34.93% |
Net Profit Margin | 16.81% | ↑ 0.89% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 308.6M | ↑ 4.39% |
Net Income | 50.0M | ↑ 3.01% |
Net Profit Margin | 16.22% | ↓ 0.21% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 330.9M | ↑ 7.26% |
Net Income | 61.3M | ↑ 22.54% |
Net Profit Margin | 18.53% | ↑ 2.31% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 351.2M | ↑ 6.12% |
Net Income | 49.4M | ↓ 19.49% |
Net Profit Margin | 14.05% | ↓ 4.48% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 383.7M | ↑ 9.26% |
Net Income | 66.0M | ↑ 33.77% |
Net Profit Margin | 17.21% | ↑ 3.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 394.1M | ↑ 2.7% |
Net Income | 68.7M | ↑ 4.0% |
Net Profit Margin | 17.42% | ↑ 0.21% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 434.1M | ↑ 10.14% |
Net Income | 72.9M | ↑ 6.15% |
Net Profit Margin | 16.79% | ↓ 0.63% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 950.7M | ↓ 2.9% |
Total Liabilities | 447.2M | ↑ 21.39% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 967.9M | ↑ 1.81% |
Total Liabilities | 378.2M | ↓ 15.42% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 18.09% |
Total Liabilities | 416.8M | ↑ 10.19% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 21.66% |
Total Liabilities | 584.9M | ↑ 40.33% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 19.36% |
Total Liabilities | 707.0M | ↑ 20.88% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↓ 18.52% |
Total Liabilities | 966.1M | ↑ 36.65% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↑ 5.25% |
Total Liabilities | 707.0M | ↑ 4.12% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 19.01% |
Total Liabilities | 739.3M | ↑ 4.57% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 2.15% |
Total Liabilities | 1.0B | ↑ 39.61% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↑ 0.99% |
Total Liabilities | 978.5M | ↓ 5.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 1.81% |
Total Liabilities | 966.1M | ↓ 1.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 3.2% |
Total Liabilities | 1.0B | ↑ 8.52% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 97.4M | ↑ 6.16% |
Investing Cash Flow | -12.2M | ↓ 8.83% |
Financing Cash Flow | -97.8M | ↑ 68.65% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 156.6M | ↑ 60.79% |
Investing Cash Flow | -17.0M | ↑ 38.7% |
Financing Cash Flow | -141.6M | ↑ 44.72% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 201.9M | ↑ 28.92% |
Investing Cash Flow | -19.1M | ↑ 12.79% |
Financing Cash Flow | -73.9M | ↓ 47.79% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 258.7M | ↑ 28.14% |
Investing Cash Flow | -31.2M | ↑ 63.05% |
Financing Cash Flow | -82.3M | ↑ 11.32% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 263.3M | ↑ 1.8% |
Investing Cash Flow | -31.4M | ↑ 0.48% |
Financing Cash Flow | -44.5M | ↓ 45.97% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 70.9M | ↓ 2.02% |
Investing Cash Flow | -9.1M | ↑ 38.12% |
Financing Cash Flow | 2.4M | ↓ 146.69% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 46.3M | ↓ 34.75% |
Investing Cash Flow | -11.2M | ↑ 22.95% |
Financing Cash Flow | -412.1M | ↓ 17051.17% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 96.6M | ↑ 108.88% |
Investing Cash Flow | -11.1M | ↓ 0.72% |
Financing Cash Flow | -123.5M | ↓ 70.04% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 108.5M | ↑ 12.29% |
Investing Cash Flow | -7.2M | ↓ 35.41% |
Financing Cash Flow | -109.1M | ↓ 11.63% |
Sell
Neutral
Buy
Medpace Holdings, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Medpace Holdings, Inc. | -1.42% | -3.02% | 42.1% | 127.13% | 383.15% |
![]() IDEXX Laboratories, Inc. | -4.22% | 10.11% | 19.74% | 50.21% | 124.29% |
![]() Agilent Technologies Inc. | -11.51% | -22.3% | -5.6% | 33.93% | 92.09% |
![]() Thermo Fisher Scientific, Inc. | -4.83% | -6.82% | -8.03% | 49.43% | 147.46% |
![]() Danaher Corp. | -3.94% | -15.07% | -11.98% | 40.41% | 129.34% |
![]() IQVIA Holdings Inc. | 4.97% | -8.52% | -7.34% | 33.49% | 98.5% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Medpace Holdings, Inc. | 25.7 | 25.7 | 1.97 | 8.2 | 0.54 | 0.14 | 0.0 | 11.37 |
![]() IDEXX Laboratories, Inc. | 55.23 | 55.23 | 7.21 | 9.69 | 0.94 | 0.22 | 0.0 | 10.13 |
![]() Agilent Technologies Inc. | 26.91 | 26.91 | 2.36 | 5.63 | 0.25 | 0.1 | 0.01 | 18.96 |
![]() Thermo Fisher Scientific, Inc. | 34.01 | 34.01 | 4.28 | 23.68 | 0.14 | 0.05 | 0.0 | 109.55 |
![]() Danaher Corp. | 25.0 | 25.0 | 3.24 | 8.74 | 0.14 | 0.06 | 0.0 | 68.31 |
![]() IQVIA Holdings Inc. | 35.62 | 35.62 | 1.48 | 10.42 | 0.18 | 0.05 | 0.0 | 31.98 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Medpace Holdings, Inc. | Buy | $6.2B | 383.15% | 25.7 | 16.44% |
![]() IDEXX Laboratories, Inc. | Buy | $38.9B | 124.29% | 55.23 | 20.38% |
![]() Agilent Technologies Inc. | Buy | $35.3B | 92.09% | 26.91 | 19.09% |
![]() Thermo Fisher Scientific, Inc. | Buy | $201.4B | 147.46% | 34.01 | 13.75% |
![]() Danaher Corp. | Buy | $171.3B | 129.34% | 25.0 | 22.4% |
![]() IQVIA Holdings Inc. | Buy | $37.0B | 98.5% | 35.62 | 7.28% |
BlackRock Inc
Vanguard Group Inc
Wasatch Advisors Inc.
Fuller & Thaler Asset Management Inc
State Street Corporation
Amvescap Plc.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,400 people across 37 countries.
Organization | Medpace Holdings, Inc. |
Employees | 5400 |
CEO | Dr. August James Troendle M.D. |
Industry | Commercial Services |
Corcept Therapeutics Inc
$23.19
-3.29%
ImmunoGen, Inc.
$13.42
-4.14%
United Therapeutics Corporation
$204.74
-1.24%
Patterson Companies, Inc.
$26.11
-1.47%
AMN Healthcare Services Inc.
$96.80
+0.59%
Integer Holdings Corp
$81.58
+1.51%
Revance Therapeutics Inc
$30.25
-0.71%
Grifols, S.A.
$8.58
-1.72%
EVOTEC SE - ADR
$10.55
-3.3%